S. Letovsky

SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations 1 Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic 2 Infection 3

A. Schuh, T. Wrin, C. Petropoulos, 2021 .

SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection

S. Letovsky, A. Schuh, A. Hall, 2021, medRxiv.

Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022

R. Iachan, A. MacNeil, R. Wiegand, 2022, The Lancet Regional Health - Americas.

SARS-CoV-2 spike-protein targeted serology test results and their association with subsequent COVID-19-related outcomes

Magdalene M. Assimon, M. Eisenberg, W. Meyer, 2023, Frontiers in public health.

Modeling COVID-19 disease biology to identify drug treatment candidates

Adam M. Sullivan, Stefan Díaz Gaisenband, W. Jessen, 2022, bioRxiv.

A computerized approach for morphological analysis of the corpus callosum.

Jerry L Prince, S. Letovsky, S. Resnick, 1996, Journal of computer assisted tomography.

Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.

A. Chenn, E. Severson, S. Ramkissoon, 2023, Cancer genetics.